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LETTER TO THE EDITOR
Jaundice in resected pancreatic cancer patients
Sir,
We enjoyed the article by Strasberg et al. emphasizing the use of
jaundice as a prognostic biomarker in patients with resected
adenocarcinoma of the pancreas.1 In our attempt to validate these
authors’ findings in our own cohort2 of 124 patients resected for
pancreatic cancer, we found median survival amounted to 28.5
months in patients without jaundice and 17.9 months in those
with jaundice. This difference was not statistically significant, but
the findings of Strasberg et al.1 have been validated by other
groups.3 Following the approach used by Strasberg et al.,1 we
found tumour size, alkaline phosphatase level, tumour–node–
metastasis (TNM) stage, grading and margin status to be signifi-
cant prognostic factors in univariate analyses. When all factors
were entered in a multivariate model, grading and margin status
remained significant. The prognostic effect of jaundice – when
present1,3 – is apparently independent of local obstruction (i.e.
tumour size, stenting and nodal status), which suggests the pres-
ence of at least some underlying metabolic differences in the liver
and/or tumour cells.4
The study by Strasberg et al.1 raises another important ques-
tion. Tumour–node–metastasis staging is probably the most
important factor in choosing treatment options and predicting
outcome (e.g. determining resectability).5 However, both our own
analysis and that of Strasberg et al.1 demonstrate larger effect sizes
of other factors, such as grading after resection. Did Strasberg
et al.1 include TNM staging in their analyses? The finding that
preoperative jaundice status outperforms postoperative staging in
predicting outcome would emphasize the clinical relevance of
jaundice as a prognostic biomarker.
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